- In July 2024, ZIM Laboratories received approval to market Azithromycin for Oral Suspension 200 mg/5ml (40 mg/ml) in Portugal. The taste-masked suspension formulation differentiates it from other products, offering a unique dosage form. This approval represents ZIM’s first marketing authorization for its novel and innovative pharmaceutical product in the European market
- In April 2023, Zydus received FDA approval for its Azithromycin production. This antibiotic, commonly used to treat a variety of infections such as bronchitis, pneumonia, and STDs, is now more readily available. The approval significantly enhances Zydus' role in healthcare by ensuring a consistent supply of Azithromycin for effective infection management
- In January 2020, Alembic Pharmaceuticals Ltd. obtained FDA approval for its generic Azithromycin tablets (USP 250 mg and 500 mg). These tablets, approved under the Abbreviated New Drug Application (ANDA), are intended for treating COVID-19. The approval marked a significant step in providing a crucial treatment option during the pandemic
